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Assessment of the Composition and Biologic Activity of Platelet Rich Plasma and its 
Relationship to Clinical Outcomes in Patients with Knee Osteoarthritis  
 
Bijan Dehghani1, Habib Zahir1, Xiaoning Yuan1, Daniel Nemirov1, Christine Kim1, Reyna 
Bhandhari1, Patrick Fava1, Yurii Chinenov1, Joseph Nguyen1, Laura Donlin1, Brian Halpern1, 
Scott Rodeo1, Miguel Otero1 
1Hospital for Special Surgery New York, New York 
Recent studies suggest positive clinical outcomes associated with platelet-rich-plasma (PRP) 
administration to treat knee osteoarthritis (OA). However, the results remain inconclusive in part 
because of the high variability in PRP preparations and the limited information regarding the 
relevant biologically active components of PRP. We hypothesize that the variability in clinical 
response is driven by the heterogeneous composition of PRP. In this study we evaluated the 
composition and biological activity of PRP and further correlated our findings to clinical outcomes 
in patients receiving intra-articular injections for knee OA. After IRB approval and patient consent, 
we enrolled 51 patients (mean age: 57.9 ± 10.1; mean BMI: 26.0 ± 4.1) with mild-moderate knee 
OA (Kellgren Lawrence grades 1-3), eligible for intra-articular PRP injection. We obtained MRI 
at baseline and outcome measures (KOOS JR and PNS) at baseline, 6 weeks, 6 months, and 12 
months after PRP injection. Patients were categorized as “good” and “poor” responders based on 
the outcome measures, corrected using published Minimally Clinically Important Difference 
(MCID) values. Aliquots of PRP and whole blood from the same patients were used to evaluate 
composition (CBC with differential and multiplex ELISA) and biologic activity, using a co-culture 
system of macrophages and fibroblast incubated with TNFa with and without PRP (10% v:v) for 
24 hours. Total RNA from cells was used for RNAseq, Nanostring, and RTqPCR analysis. On 
average, we collected 4.07 ± 01.05 mL of PRP, and 3.24 ± 0.85 mL of PRP were injected intra-
articularly. PRP preparations yielded mean fold-changes of 1.60 ± 0.37 platelets and 0.19 ± 0.08v 
leukocytes, relative to whole-blood from the same patients (set as 1). On average, all patients that 
reached the 6-month time-point (N = 32) reported improved outcomes at 6-weeks and 6-months 
after PRP administration (KOOS and PNS p<0.05 vs. baseline). After MCID corrections, we 
identified “good” (N=17, positive response using both measures) and “poor” responders (N=15, 
poor response in one or both measures). RNAseq analyses showed PRP-dependent changes in the 
TNFa-induced modulation of a number of genes, including CXCL7 and CCL5. NanoString and 
RTqPCR analyses confirmed the RNAseq results. Comparisons of PRP from good and poor 
responders identified changes in the composition and biologic activity between these groups. This 
pilot study integrated clinical data with genomic approaches to evaluate variability in the 
composition and activity of PRP, and how this may influence outcomes in patients with knee OA. 
We uncovered subsets of genes differentially modulated by co-treatment of PRP with TNFa, in 
agreement with the concept that the reduced knee OA pain in patients treated with PRP is driven 
by the ability of PRP to modulate inflammation. Furthermore, we identified changes in the 
composition and biologic activity of PRP between “good” and “poor” responders.  
 
 
